8-K: Calidi Biotherapeutics Holds Annual Meeting, Approves Key Proposals

Calidi Biotherapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all presented proposals, including director election, auditor ratification, a reverse stock split, and a plan amendment, were approved.

Summary

• Calidi Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 12, 2026.
• A quorum was established with approximately 55.29% of outstanding shares represented.
• All proposals presented to stockholders were approved.
• Scott Leftwich was elected as a Class III Director for a three-year term.
• CBIZ CPAs P.C. was ratified as the independent auditor for the fiscal year ending December 31, 2026.
• Stockholders approved an amendment to allow for a reverse stock split, with a ratio between 1-for-2 and 1-for-16, to be determined by the Board of Directors.
• An amendment to the 2023 Equity Incentive Plan was approved, increasing the authorized shares from 282,815 to 1,950,000.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it confirms shareholder support for key corporate actions, including a potential reverse stock split and increased equity incentives, which are generally seen as enabling future growth and flexibility.

Positives

• All key proposals presented at the annual meeting were approved by stockholders.
• A new Class III Director, Scott Leftwich, was elected to serve a three-year term.
• The appointment of CBIZ CPAs P.C. as the independent auditor was ratified.
• Shareholder approval was obtained for a reverse stock split, providing flexibility for future capital structure adjustments.
• The company received approval to increase the share pool for its 2023 Equity Incentive Plan, supporting future employee and executive compensation.

Negatives

• A significant number of shares were withheld from voting on the election of the director nominee (1,376,756 shares).
• A substantial number of broker non-votes were recorded for the director election (3,584,915 shares), indicating a lack of direct shareholder instruction on this matter.
• The reverse stock split proposal received a notable number of 'against' votes (1,835,715 shares).
• The amendment to the 2023 Equity Incentive Plan also saw a considerable number of 'against' votes (1,423,374 shares).

Risks

• The reverse stock split, while approved, will be implemented at the discretion of the Board of Directors within a specified range, introducing uncertainty regarding the exact ratio and timing.
• The increase in authorized shares for the equity incentive plan could lead to significant dilution if not managed carefully.
• The substantial number of broker non-votes on director elections may indicate a lack of engagement or confidence from a portion of the shareholder base.

Future Outlook

The Board of Directors has the discretion to effect a reverse stock split within a ratio of 1-for-2 to 1-for-16. The 2023 Equity Incentive Plan has been amended to increase the aggregate number of authorized shares.

Management Comments

• All proposals presented for a vote at the Annual Meeting were approved by the Company's stockholders.

Industry Context

StockSavvy.ai notes that the approval of a reverse stock split is a common corporate action taken by companies, particularly those in the biotechnology sector, to increase the per-share market price of their stock, potentially making it more attractive to institutional investors and meeting exchange listing requirements. The increase in equity incentive shares is also typical for growth-stage companies aiming to attract and retain talent.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Approved actions that could impact share structure (reverse split) and future equity dilution (incentive plan increase).
• Employees: Benefit from the increased equity available under the 2023 Equity Incentive Plan.
• Management: Gained flexibility to implement a reverse stock split and increased capacity for equity-based compensation.

Next Steps

• The Board of Directors will determine the specific ratio for the reverse stock split within the approved range (1-for-2 to 1-for-16) and will make a public announcement.
• The company will proceed with the amendment to the 2023 Equity Incentive Plan, increasing the authorized shares.
• Scott Leftwich will serve as a Class III Director until the 2029 Annual Meeting of Stockholders.

Key Dates

Recommendation

The filing details routine corporate governance matters and shareholder approvals for actions like a reverse stock split and equity plan amendments. While these actions can be enabling for future growth, they do not provide new operational or financial performance data that would warrant a change in investment recommendation based solely on this filing.

Keywords

Calidi Biotherapeutics, Annual Meeting, Stockholder Vote, Director Election, Auditor Ratification, Reverse Stock Split, Equity Incentive Plan, Form 8-K